PROTHENA CORP PUBLIC LTD CO (PRTA)

Pharmaceutical Preparations · market cap $449M · as of 2026-07-07

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-05 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Prothena Corp (PRTA) is a clinical-stage biopharma with a market cap of ~$497M and a single disclosed pipeline asset, NEOD001, in Phase 2 for Primary (AL) Amyloidosis. The company holds $329.5M in cash against a net loss of $244M in 2025, implying a burn-adjusted cash position that is meaningful relative to its market cap. Revenue has been lumpy and partnership-dependent, swinging from $201M in 2021 to $10M in 2025.

The catalyst path

2026-11-05 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
NEOD001	Phase 2	Primary Amyloidosis

Price & technical context

3-month

-9.8%

6-month

-13.1%

12-month

-13.6%

52-wk range

$7.91–$11.51

vs 50-day MA

-3.5%

vs 200-day MA

-8.1%

Realized vol

47.3%

Max drawdown

-79.3%

Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for PRTA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.